%20(5).png)
India’s value-driven e-commerce space is rapidly expanding, and Meesho has emerged as a dominant disruptor—serving Tier-2 & Tier-3 buyers underserved by Amazon and Flipkart. With the IPO opening on December 3, 2025, here’s an in-depth analysis for investors.
Issue Open: December 3, 2025
Issue Close: December 5, 2025
Total Issue Size: ₹5,421.20 crore
Fresh Issue: ₹4,250 crore
Offer for Sale: ₹1,171.20 crore
Price Band: ₹105–₹111
Market Lot: 135 shares
Estimated M-Cap: ₹50,095.75 crore
Listing: BSE & NSE
Issue Allocation:
Use of Funds:
Founded in 2015, Meesho is a multi-sided value-commerce marketplace connecting:
Strong, consistent rise in volume & efficiency.
FY25 losses reflect one-time accounting items, not operational weakness.
Margins improving steadily.
Negative earnings are typical during the scaling phase of digital platforms.
Shows solid unit economics despite accounting losses.
India’s most underpenetrated and fastest-growing segment.
Boosts seller margins → drives affordability.
Meesho is the only pure-play value e-commerce listed/going public.
AI helps across:
Meesho
Zomato
Swiggy
Brainbees (FirstCry)
Nykaa (FSN)
Trent
Avenue Supermarts (DMart)
Conclusion:
Meesho’s ~5.5× Sales valuation is reasonable compared to premium peers.
1. Is Meesho profitable?
Not yet. Losses continue due to one-off items, but cash flow is positive.
2. Why is the Meesho IPO attractive?
Affordable valuation, strong growth, and value-commerce dominance.
3. Main risks for investors?
Competition, quality issues, COD dependency.
4. Is the valuation reasonable?
Yes—~5.5× Sales, cheaper than Zomato & Nykaa.
5. Who should apply?
Aggressive, long-term tech investors.
.png)
Nvidia’s Q3 fiscal-2026 results were nothing short of spectacular. The company clocked $57.0 billion in revenue, a 22% increase quarter-over-quarter and a massive 62% year-over-year jump.
The data-centre business, which fuels much of Nvidia’s strength, reported $51.2 billion — up 25% sequentially and a whopping 66% YoY.
Earnings per share (diluted) stood at $1.30, beating market expectations. Gross margins remained healthy: ~73.4% on a GAAP basis and ~73.6% on non-GAAP.
Jensen Huang, Nvidia’s CEO, painted a bold picture: “Blackwell sales are off the charts, and cloud GPUs are sold out … We’ve entered the virtuous cycle of AI.”
On the capital return front, Nvidia has distributed $37 billion to shareholders via buybacks and dividends in the first nine months of fiscal 2026, while still retaining $62.2 billion under its repurchase authorization.
Nvidia’s blazing growth is a clear sign that AI infrastructure is scaling up rapidly. For Indian cloud service providers, startups, and large enterprises, this means greater access to powerful compute — and hence more opportunity to build or scale AI-driven products, whether in generative AI, autonomous systems, or large-language-model applications.
IT services companies such as TCS, Infosys, HCL Tech, and Wipro stand to benefit in multiple ways:
India has long expressed ambitions to build a vibrant semiconductor ecosystem. Nvidia’s strong earnings fuel confidence in the global semiconductor demand outlook — which may in turn accelerate semiconductor-related investments in India.
While Nvidia’s results are a vote of confidence in the AI era, Indian investors and companies should also remain aware of potential headwinds:
For Indian investors looking to play the Nvidia or AI-infrastructure story:
Q1. Does Nvidia’s strong result mean an “AI bubble” is safe to ignore?
Not entirely. While Nvidia’s performance reinforces real demand, investors should maintain a balanced view — growth is strong, but it’s not without risks like supply chain bottlenecks, valuation, and geopolitical concerns.
Q2. How exactly will Indian semiconductor manufacturing benefit from Nvidia’s growth?
Higher global demand for AI chips strengthens the case for semiconductor investments in India. This could encourage more fabs, design centres, and collaborations if Indian policy and capital conditions align.
Q3. Should I invest in Nvidia directly or via Indian IT companies?
Both routes have merit. Direct exposure (NVDA shares) gives pure-play access, but investing in Indian IT companies offers leverage to India’s AI ecosystem growth, possibly with lower volatility and regulatory simplicity.
Q4. How does Swastika Investmart help in this context?
Swastika Investmart is SEBI-registered, offers powerful research tools, and supports international investing. Use its platform for guided insights, risk analysis, and thematic portfolios around AI/semiconductors.
Nvidia’s Q3 earnings are a resounding signal that AI infrastructure is accelerating, and the ripple effects could meaningfully shape the future of Indian technology markets. For Indian investors and corporations alike, this is more than just a U.S. company doing well — it’s an opportunity that aligns with India’s tech ambitions, semiconductor goals, and digital transformation journey.
If you’re looking to position yourself for this wave, Swastika Investmart offers the tools, trust, and technology to help you navigate global markets smartly. Open an account today and explore:
कमोडिटी फ्यूचर्स एक ऐसा डेरिवेटिव कॉन्ट्रैक्ट होता है, जिसमें आप किसी कमोडिटी (जैसे गोल्ड, क्रूड ऑयल, सिल्वर, या कॉपर) को भविष्य की तारीख पर तय कीमत पर खरीदने या बेचने का समझौता करते हैं।
उदाहरण के तौर पर —
अगर आप मानते हैं कि क्रूड ऑयल की कीमत बढ़ेगी, तो आप उसका फ्यूचर कॉन्ट्रैक्ट खरीदते हैं।
अगर कीमत बढ़ती है, तो आपको मुनाफा होता है; अगर गिरती है, तो नुकसान।
कमोडिटी ट्रेडिंग में सिर्फ कीमतें देखना पर्याप्त नहीं है।
डेटा एनालिसिस (OI, Volume, Rollover) से आप यह समझ सकते हैं कि —
इसलिए एक समझदार ट्रेडर के लिए फ्यूचर्स डेटा पढ़ना उतना ही ज़रूरी है जितना चार्ट देखना।
Open Interest (OI) बताता है कि किसी खास कमोडिटी फ्यूचर में कितने ओपन कॉन्ट्रैक्ट्स अभी तक क्लोज़ नहीं हुए हैं।
यह ट्रेंड की मजबूती और भागीदारी को दर्शाता है।
हर फ्यूचर कॉन्ट्रैक्ट की एक एक्सपायरी डेट होती है (आमतौर पर महीने के आखिरी सप्ताह में)।
अगर ट्रेडर अपनी पोजीशन को अगले महीने के कॉन्ट्रैक्ट में शिफ्ट करता है, तो इसे Rollover कहा जाता है।
उदाहरण:
अगर सिल्वर में 85% Rollover दिख रहा है, तो इसका मतलब है कि ज़्यादातर ट्रेडर्स ने अपनी लंबी पोजीशन को अगले महीने तक बढ़ा लिया है — यानी सकारात्मक सेंटिमेंट जारी है।
ट्रेडिंग में सही निर्णय लेने के लिए आपको तीनों डेटा को एक साथ पढ़ना चाहिए।स्मार्ट ट्रेडिंग टिप:
सिर्फ प्राइस देखकर ट्रेड न करें — OI और Volume की पुष्टि ज़रूर करें।
अधिकांश ब्रोकर्स जैसे Swastika Investmart अपने ग्राहकों को Futures Analytics Tools प्रदान करते हैं।
इनसे आप रियल-टाइम OI, Rollover और Volume डेटा देख सकते हैं।
Swastika Investmart के प्लेटफॉर्म पर:
👉 यहाँ क्लिक करें और डेटा देखें
भारत का कमोडिटी डेरिवेटिव मार्केट (MCX, NCDEX) विश्व के सबसे तेज़ी से बढ़ते बाजारों में से एक है।
यहाँ गोल्ड, सिल्वर, क्रूड, कॉपर, और एग्री-कमोडिटीज़ में रोज़ाना अरबों रुपये का कारोबार होता है।
सरकार और SEBI के सख्त नियामक ढाँचे के कारण यह मार्केट अब पहले से कहीं ज़्यादा पारदर्शी और निवेशक-अनुकूल बन गया है।
Swastika Investmart एक SEBI-registered broker है, जो कमोडिटी, इक्विटी और डेरिवेटिव ट्रेडिंग में
अपने रिसर्च-बेस्ड एनालिटिक्स टूल्स और ग्राहक समर्थन के लिए प्रसिद्ध है।
Swastika के साथ आपको मिलता है:
👉 अभी खाता खोलें और डेटा-ड्रिवन ट्रेडिंग शुरू करें।
1️⃣ OI क्या दर्शाता है?
OI दिखाता है कि मार्केट में कितने ओपन कॉन्ट्रैक्ट्स हैं — यह भागीदारी और ट्रेंड की मजबूती बताता है।
2️⃣ Rollover कैसे समझें?
अगर ज़्यादातर ट्रेडर्स अपनी पोजीशन अगले महीने ले जा रहे हैं, तो Rollover हाई होता है — इसका मतलब है कि ट्रेंड में विश्वास बना हुआ है।
3️⃣ क्या OI डेटा रोज़ बदलता है?
हाँ, हर दिन जब भी नए कॉन्ट्रैक्ट्स जुड़ते या खत्म होते हैं, OI डेटा अपडेट होता है।
4️⃣ Futures Trading में यह डेटा क्यों ज़रूरी है?
क्योंकि यह बताता है कि “पैसा कहाँ जा रहा है” — यानी स्मार्ट मनी किस दिशा में ट्रेड कर रही है।
5️⃣ क्या मैं Swastika पर यह डेटा लाइव देख सकता हूँ?
हाँ, Swastika के डैशबोर्ड में रियल-टाइम OI, Volume और Rollover डेटा उपलब्ध है।
कमोडिटी फ्यूचर्स डेटा को समझना हर निवेशक और ट्रेडर के लिए एक महत्वपूर्ण स्किल है।
OI और Rollover से आप सिर्फ ट्रेंड नहीं, बल्कि मार्केट की गहराई और मूड समझ सकते हैं।
अगर आप डेटा-आधारित ट्रेडिंग सीखना चाहते हैं और बेहतर निर्णय लेना चाहते हैं — Swastika Investmart के साथ जुड़ें
%20(2)%20(5).png)
The Sudeep Pharma IPO is among the most talked-about offerings this month, thanks to its strong financial performance and leadership position in pharma-grade minerals and excipients. With subscription dates 21–25 November 2025, investors are evaluating whether the steep valuation is justified by the company’s growth story.
This detailed analysis covers the company’s fundamentals, market position, valuations, strengths, risks, and whether retail investors should consider applying.
Founded in 1989, Sudeep Pharma has grown into one of India’s key manufacturers of pharmaceutical excipients and specialty chemicals, supplying more than 200+ products across pharma, food, and nutrition sectors. The company operates six manufacturing facilities with a combined capacity of 50,000 MT and serves several global blue-chip clients.
Their product portfolio includes:
Importantly, Sudeep Pharma holds prestigious global certifications such as US FDA, WHO-GMP, EXCiPACT, ISO 9001, FSSC 22000, HACCP, Kosher, and Halal, positioning the company as a trusted supplier in regulated markets.
In 2025, the company also acquired a European premix manufacturer (NSS), strengthening its foothold in the nutrition business.
Detail Information
Issue Size- ₹895 cr
Fresh Issue- ₹95 cr
OFS- ₹800 cr
Price Band- ₹563–593
Market Lot- 25 shares
Issue Dates- 21–25 Nov 2025
Post-issue Market Cap- ₹6,697.85 cr
Listing- BSE & NSE
The IPO consists largely of an Offer for Sale, meaning most proceeds go to existing shareholders, not the company. Only the fresh issue will fund capex for machinery at the Nandesari facility and general corporate expenses.
This is an impressive trend—both revenue and profitability have shown robust improvement. A near-40% EBITDA margin places Sudeep among the better-performing players in India’s specialty chemicals space.
Based on FY25 financials:
This valuation is on the higher side, even for high-quality pharma ingredient companies. The IPO note itself categorizes the issue as “aggressively priced”, indicating that most near-term growth is already factored into the pricing.
Not significantly. The valuation restricts the short-term upside. Investors looking for 10–20% short-term gains may find the risk-reward unfavourable.
If the company continues delivering:
then the valuation could still be justified over a multi-year horizon.
Manufacturing mineral-based excipients requires high R&D expertise, compliance systems, and technical know-how—creating strong entry barriers.
Sudeep Pharma Ltd. IPO note (1)
Sudeep serves several Fortune 500 and global blue-chip clients. Long-term contracts and consistent quality make the business sticky.
Regulated market approvals (e.g., US FDA, EXCiPACT) give the company a competitive advantage, especially in the pharma excipients space.
Multiple in-house labs, pilot plants, and a team dedicated to mineral salts innovation drive product development.
Even strong companies carry risks. For Sudeep Pharma, key concerns include:
This increases vulnerability to client or segment-level slowdowns.
All manufacturing facilities are located in Gujarat, exposing operations to regional disruptions.
Failure to pass audits from global pharma clients could lead to immediate order loss.
4. M&A Integration Risk
Integrating NSS or future acquisitions may strain resources or fail to deliver expected synergies.
The fundamentals are strong: high margins, diversified products, global certifications, and solid financial growth. However, valuation is steep, reducing the probability of short-term listing gains.
The IPO opens on 21 November 2025 and closes on 25 November 2025.
The price band is ₹563–593 per share.
The IPO is aggressively priced, leaving limited room for short-term gains. Suitable mainly for long-term investors.
Primarily for capex—procurement of machinery for the Nandesari facility—and general corporate purposes.
No direct listed peers exist in India in the same line of business.
Invest in upcoming IPOs, equities, and mutual funds with a trusted SEBI-registered broker. Swastika Investmart offers powerful research tools, strong customer support, and a seamless tech-enabled platform.
%20(12).png)
Demat Account (Dematerialized Account) वह खाता होता है जिसमें आपके शेयर, म्यूचुअल फंड और बॉन्ड्स इलेक्ट्रॉनिक रूप में रखे जाते हैं।
यह बैंक खाते की तरह काम करता है — बस फर्क इतना है कि इसमें पैसे की जगह शेयर होते हैं।
अगर आप किसी और के साथ मिलकर निवेश करना चाहते हैं, तो आप एक Joint Demat Account खोल सकते हैं।
Joint Demat Account में दो या तीन व्यक्ति मिलकर एक ही Demat खाता खोल सकते हैं।
इसमें एक व्यक्ति को Primary Holder (मुख्य धारक) कहा जाता है और बाकी को Joint Holder(s)।
उदाहरण के तौर पर:
मान लीजिए, आप अपने जीवनसाथी या भाई के साथ मिलकर शेयर निवेश करना चाहते हैं।
ऐसे में आप दोनों एक Joint Demat Account खोल सकते हैं, ताकि शेयर और लाभ साझा रूप से रखे जा सकें।
भारत में दो प्रमुख Depositories हैं — NSDL और CDSL।
आपको इनके अधिकृत DP जैसे Swastika Investmart के माध्यम से खाता खोलना होगा।
👉 Swastika Investmart पर ऑनलाइन खाता खोलें
सभी धारकों को नीचे दिए गए दस्तावेज़ जमा करने होंगे:
सभी applicants को KYC (Know Your Customer) पूरी करनी होती है।
अगर आप ऑनलाइन प्रक्रिया चुनते हैं, तो Aadhaar आधारित e-KYC और e-Sign से पूरा हो जाता है।
आप अपने Joint Demat Account में Nominee जोड़ सकते हैं।
Nominee केवल Primary Holder द्वारा तय किया जा सकता है, लेकिन भविष्य में इसे बदला जा सकता है।
सभी दस्तावेज़ सत्यापित होने के बाद, DP द्वारा खाता सक्रिय किया जाता है।
आपको Login credentials मिलेंगे जिससे आप अपने होल्डिंग्स और ट्रांज़ैक्शन्स देख सकते हैं।
Joint Mode- सभी धारकों के हस्ताक्षर हर ट्रांज़ैक्शन के लिए आवश्यक होते हैं।
Either or Survivor Mode- किसी भी एक धारक के सिग्नेचर से ट्रांज़ैक्शन संभव है (अक्सर पति-पत्नी के खातों में)।
✅ साझा निवेश नियंत्रण – परिवार या पार्टनर के साथ निवेश प्रबंधन आसान।
✅ उत्तराधिकार में सरलता – मृत्यु की स्थिति में दूसरे धारक को स्वामित्व मिल जाता है।
✅ पारदर्शिता – सभी धारक समान रूप से लेनदेन देख सकते हैं।
✅ सुविधाजनक रिकॉर्ड कीपिंग – एक ही खाता, एकीकृत पोर्टफोलियो ट्रैकिंग।
Swastika Investmart एक SEBI-registered, NSDL/CDSL depository participant है,
जो निवेशकों को भरोसेमंद और तकनीक-सक्षम अनुभव देता है।
Swastika के साथ आपको मिलता है:
👉 अभी खाता खोलें और परिवार के साथ समझदारी से निवेश शुरू करें।
1️⃣ क्या मैं अपने माता-पिता या जीवनसाथी के साथ Joint Demat Account खोल सकता हूँ?
हाँ, आप किसी भी वयस्क भारतीय निवासी के साथ संयुक्त खाता खोल सकते हैं।
2️⃣ क्या NRI संयुक्त धारक बन सकता है?
हाँ, लेकिन उसे FEMA और RBI दिशा-निर्देशों का पालन करना होगा।
3️⃣ क्या सभी धारकों को KYC देना होता है?
हाँ, प्रत्येक धारक को अलग-अलग KYC और PAN कार्ड की आवश्यकता होती है।
4️⃣ अगर एक धारक की मृत्यु हो जाए तो क्या होगा?
ऐसी स्थिति में खाता Survivor के नाम पर ट्रांसफर किया जा सकता है।
5️⃣ क्या Swastika Investmart में यह प्रक्रिया ऑनलाइन है?
हाँ, पूरी प्रक्रिया e-KYC और e-Sign के माध्यम से ऑनलाइन पूरी की जा सकती है।
एक Joint Demat Account आपको अपने परिवार या पार्टनर के साथ निवेश की जिम्मेदारी साझा करने की सुविधा देता है।
यह पारदर्शिता, सुरक्षा और आसान उत्तराधिकार की दृष्टि से एक समझदार विकल्प है।
Excelsoft Technologies Limited is gearing up for its public debut, and the IPO has already drawn attention because of its niche positioning in the vertical SaaS EdTech market. The company provides AI-enabled learning, assessment, and digital content solutions to global clients — a space that has seen rapid adoption across corporate, academic, and certification ecosystems.
With Swastika Investmart’s in-depth research backing the IPO note, this article breaks down the business fundamentals, valuation, risks, and whether investors should apply.
Excelsoft Technologies is a global vertical SaaS company specializing in the learning, assessment, and education technology ecosystem. Their products are used by academic institutions, corporates, government bodies, and certification agencies across multiple geographies.
A recurring-revenue, SaaS-driven platform model catering to global education and training markets — with long-term sticky clients.
IPO Size: ₹500 crore
Fresh Issue: ₹180 crore
OFS: ₹320 crore
Price Band: ₹114–₹120
Market Lot: 125 shares
Face Value: ₹10
Listing: BSE, NSE
Market Cap at Upper Band: ₹1,381.01 crore
Issue Opens: 19 Nov 2025
Issue Closes: 21 Nov 2025
Listing Date26 Nov 2025
Funds will be used for:
This signals expansion capacity and infrastructure strengthening — key for SaaS scale-ups.
The company is clearly moving toward improving profitability while scaling.
EdTech, assessments, and learning automation are gaining traction globally — especially post-digital transformation.
76 clients across multiple continents.
Long-term contracts promote predictable recurring revenue.
Experienced team and mature product suite — SARAS, OpenPage, EnablED — built on agile and flexible technology.
AI-enabled proctoring, remote assessment, and digital exams are now standard for institutions and certification bodies.
This is the biggest red flag.
Any renegotiation or loss of this client can materially impact revenue.
Operating across countries brings complex regulatory exposure.
Given sensitive student data and assessment records, any cyber breach can hurt trust & revenue.
Subscription-based revenue shifts can delay recognition.
Renewal risks remain — despite repeat business.
Conclusion:
The pricing looks aggressive, considering the:
Overall Verdict: Neutral
1. What is the size of Excelsoft Technologies’ IPO?
Total size is ₹500 crore including ₹180 crore fresh issue + ₹320 crore OFS.
2. What are the key strengths of the company?
Strong global SaaS presence, long-term client relationships, AI-enabled products, and a healthy financial profile.
3. What is the biggest risk of investing in this IPO?
Excelsoft depends heavily on one client — Pearson — contributing ~59% of revenue.
4. Is the IPO fairly priced?
At P/E ~35×, it appears on the expensive side relative to risk factors.
5. What is Swastika Investmart’s view?
A Neutral rating, indicating moderate prospects and valuation concerns.
.png)
Reports indicate that BC Investments IV, a Bain Capital–affiliated entity, plans to offload about 2.4% of its stake in Emcure Pharma via a block deal. The transaction is pegged at around ₹551 crore, with a floor price of ₹1,279.80 per share. As per regulatory filings, the shares sold will come with a 90-day lock-in.
The deal is being managed by Kotak Securities, which is acting as the lead manager. As of March 2025, BC Investments IV held around 8.68% of Emcure.
The news of a large investor reducing its position tends to trigger two broad reactions:
1. Short-term sell-off:
Some shareholders may view the block deal as profit-taking, leading to short-term selling pressure. Reports suggest that Emcure’s stock dipped modestly after the news broke.
2. Questioning long-term commitment:
Even though Bain Capital isn’t exiting fully, reducing exposure could make investors wonder about its confidence in Emcure’s mid-to-long term trajectory.
At the same time, this might be a liquidity window for other investors — a chance to buy into a well-performing company at a slightly lower price.
While the block deal grabs headlines, Emcure’s business momentum remains robust.
These results suggest that operationally, Emcure is not weakened by the block-deal event.
It’s important to view this block deal in light of recent regulatory changes. SEBI, India’s markets regulator, has updated rules for block deals: the minimum size has been increased, and new price-window norms have been introduced.
These reforms aim to bring more structure and transparency to large-volume trades. For institutional sellers like Bain Capital, it also means more disciplined exit mechanisms, which may mitigate investor overreaction.
Here’s how this block deal could influence investor sentiment going forward:
Q: Why is Bain Capital selling a part of its stake in Emcure Pharma?
A: The block deal could be driven by profit booking or portfolio rebalancing. It does not necessarily signal a lack of faith in Emcure’s growth.
Q: Is Emcure's business under pressure?
A: Not based on its latest financials — in Q1 FY26, Emcure reported strong revenue and PAT growth, both domestically and internationally.
Q: Could the block deal lead to a long-term drop in share price?
A: It depends. While large stake sales can increase volatility, Emcure’s fundamentals are still strong. Long-term investors might view the dip as a buying opportunity; short-term traders could be cautious.
Q: How do SEBI’s new block deal rules affect such transactions?
A: SEBI has raised the minimum size for block deals and introduced stricter pricing windows and transparency measures, which could curb speculative or disorderly trades.
Q: How can retail investors take advantage of this situation?
A: Retail investors can use a reliable, SEBI-registered platform like Swastika Investmart, which offers research tools, educational resources, and real-time data to analyze such developments and make informed decisions.
The Emcure Pharma block deal — with Bain Capital offloading around 2.4% of its stake — is a notable event for the stock. But while it raises some eyebrow-raising questions about promoter intent, the company’s strong Q1 performance, healthy international growth, and strategic consolidation suggest that its core story remains intact.
For long-term investors, this could be a window of opportunity, provided you're comfortable with potential short-term volatility. And if you’re looking for a trusted partner to navigate such market moments, Swastika Investmart stands out — SEBI-registered, backed by quality research tools, and committed to investor education.
Trust Our Expert Picks
for Your Investments!
.webp)
.png)
.png)
